EFFECT OF DIFFERENT TYPES OF LEUKOCYTE FILTERSON ERYTHROCYTE DONOR BLOOD PRODUCTS AT THEY PRODUCTIONSTAGE LEUKODEPLETION



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

To evaluate the side effects of “production” leukofilters (LF) on filtering blood components, in particular - determine the degree of loss of hemoglobin at leykodepletion (LD) of erythrocyte blood components with various types of LF. The study of this parameter is necessary for determining reasonable criteria for selecting the type LF for everyday work in the production of red blood cell suspension (RBC’S), which would be most consistent with the concept of the “ideal”. Materials and Methods: Blood systems «Leukotrap RCPL» (production of «Pall Medical», USA) with integrated LF and «Demotec» (production of «Demophorius», Cyprus), which fluster LF “Leykosep» (production Company NLP «Interoko», Russia) were used for collection of donor blood. Results and discussion: 22 samples of leukodepleted RBC’S with LF “Leykosep” and 20 samples of RBC’S after LF «Pall» were examined for. Prior to the LD groups were quite comparable. The process of executing the LD leads to a significant reduction in the volume of the container contents and, accordingly, the loss of hemoglobin in the system with a reduction of its content in a dose of RBC’S. However, indicators of volume loss and reduction of hemoglobin in the “Interoko” group were significantly greater than in the group «Pall», which appear to be associated with the design of the LF. Accordingly, in the group “Interoko” amount of hemoglobin per dose of RBC’S was significantly less than in the group «Pall». At the same time revealed the difference between the groups in hemoglobin concentration after LD was on the damage trend without reaching statistical significance (p = 0.053), which may indicate an insufficient value of groups. However, indicators of hemoglobin concentration were within adequate values (N > 40 g / dose) to meet the requirements of Technical regulations. Conclusions: Given the increasing number of proposals on the market LF existing assessment criteria (subjective convenience for staff, the producer price) becomes clearly insufficient, moreover it turns out that the use of different types of systems at least makes it necessary to clarify the accounting for losses of erythrocyte blood products in the LF. The study makes it clear that the manufacturer’s instructions to the LF and work instructions for the LD of erythrocyte blood components should include additional criteria - a loss of volume in the LF, which entails a significant reduction in hemoglobin content.

Full Text

Restricted Access

About the authors

A E Belyaev

City hospital №15, Saint-Petersburg

A N Mironenko

City hospital №15, Saint-Petersburg

S M Platonov

City hospital №15, Saint-Petersburg

References

  1. Жибурт Е.Б., Голубева А.В., Мартынова М.В. Неблагоприятные эффекты, связанные с лейкоцитами, при гемотрансфузиях в хирургии // Вестник хирургии им. И.И. Грекова. 2001. №6. С.35-42.
  2. Колосков А.В. Иммунные негемолитические реакции и осложнения гемотрансфузий // Гематология и трансфузиология. 2004. Т.49. №3. С.35-42.
  3. Кузнецова Ю.В. Обзор научной литературы по проблеме удаления лейкоцитов из донорской плазмы // Трансфузиология. 2005. №2. С.108-114.
  4. Максимов В.А. Инфекционная и антиагрегационная безопасность крови и ее компонентов // Главврач. Ежемесячный научно-практический журнал. 2008. №11. С.45-50.
  5. Постановление Правительства РФ от 26 января 2010 г. № 29 «Об утверждении технического регламента о требованиях безопасности крови, ее продуктов, кровезамещающих растворов и технических средств, используемых в трансфузионно-инфузионной терапии» // Российская газета. 29.01.2010 г.
  6. Суханов Ю.С., Максимов В.А. Лейкофильтрация и карантинизация плазмы донорской крови // Вестник службы крови России. 2003. №3. С.12-14.
  7. Техническое руководство Американской Ассоциации Банков Крови // пер. с англ. Милан: Европейская школа трансфузионной медицины. 2000. С 611-612.
  8. Blajchman M.A.,Vamvakas E.C. The Continuing Risk of Transfusion-Transmitted Infections // The N. Eng. J. of Med. 2006. V.355 (13). Р.1303-1305.
  9. Dodd R.Y. Current Risk for Transfusion-Transmitted Infections // Curr. Opin. Hematol. 2007. V.14 (6). Р.671-676.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2015 Belyaev A.E., Mironenko A.N., Platonov S.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies